Kelly Klunt

AGENCY BILL ANALYSIS - 2025 REGULAR SESSION

WITHIN 24 HOURS OF BILL POSTING, UPLOAD ANALYSIS TO

<u>AgencyAnalysis.nmlegis.gov</u> and email to <u>billanalysis@dfa.nm.gov</u> (Analysis must be uploaded as a PDF)

SECTION I: GENERAL INFORMATION

{Indicate if analysis is on an original bill, amendment, substitute or a correction of a previous bill}

Date Prepared :	2/21/25	Check all that apply:		
Bill Number:	HB505	Original	X	Correction
		Amendment Substitute		Substitute

		Agency Name and Code	HC	A 630
Sponsor:	Rep. Cristina Parajon	Number:		
Short	Opioid use Disorder Drug	Person Writing		Keenan Ryan
Title:	Stocks	Phone: <u>505.396</u>	.0223	Email Keenan.ryan@hca.nm.

SECTION II: FISCAL IMPACT

APPROPRIATION (dollars in thousands)

Appropr	iation	Recurring	Fund	
FY25	FY26	or Nonrecurring	Affected	
\$0.0	\$0.0	N/A	N/A	

(Parenthesis () indicate expenditure decreases)

REVENUE (dollars in thousands)

Estimated Revenue			Recurring	Fund
FY25	FY26	FY27	or Nonrecurring	Affected
\$0.0	\$0.0	\$0.0	N/A	N/A

(Parenthesis () indicate revenue decreases)

ESTIMATED ADDITIONAL OPERATING BUDGET IMPACT (dollars in thousands)

	FY25	FY26	FY27	3 Year Total Cost	Recurring or Nonrecurring	Fund Affected
Total	\$0.0	\$0.0	\$0.0	\$0.0	N/A	N/A

(Parenthesis () Indicate Expenditure Decreases)

SECTION III: NARRATIVE

BILL SUMMARY

<u>Synopsis:</u> HB505 looks to create a minimum stocking standard of buprenorphine products for pharmacies. Retail pharmacies must determine the average buprenorphine stocking requirement over the past thirty days. The pharmacy must maintain a quantity of buprenorphine that is equivalent to the thirty-day quantity plus three additional buprenorphine prescriptions.

Pharmacies can be penalized for not meeting this standard; however, it outlines reasonable action the pharmacy can be attempt that would prevent said penalties. This includes working with the wholesalers to increase the pharmacy's allotment of buprenorphine.

In addition, the bill creates reporting requirements for wholesalers who must disclose to the board of pharmacy relating to denials, delays of buprenorphine orders. The board of pharmacy is tasked with using this information to make a biannual report

FISCAL IMPLICATIONS

Medicaid is not in charge of overseeing the stipulations of this bill as such there is no expected fiscal impact of this legislation.

SIGNIFICANT ISSUES

Recently there has been difficultly for some pharmacies to order and dispense sufficient amounts of buprenorphine. <u>This issue</u> stems from recent federal requirements from opioid manufacturer settlements. This bill attempts to address this issue in the long term by increasing the stocking requirements and reporting. In the short term this legislation could potentiate a shortage, as retail pharmacies will attempt to increase stocking quantities at the same time.

There is a cost associated with stocking this medication for pharmacies. The cost of the three additional prescriptions for the pharmacies remains unrecouped in perpetuity.

PERFORMANCE IMPLICATIONS

None

ADMINISTRATIVE IMPLICATIONS

None No IT impact. **CONFLICT, DUPLICATION, COMPANIONSHIP, RELATIONSHIP** None

TECHNICAL ISSUES

This bill has no provision for drug shortages. Drugs shortage, unfortunately, are not rare. Additionally, their shortage can have a cascading effect in which the shortage of one medication or dose, causes other related agents or dosages to then go into shortage due their increased use during that time. This could increase pharmacies' risk for penalties for circumstances that are out of control.

OTHER SUBSTANTIVE ISSUES

None

ALTERNATIVES None

WHAT WILL BE THE CONSEQUENCES OF NOT ENACTING THIS BILL

Status quo, there may be individuals who are unable to access buprenorphine due insufficient stock or ordering limitations

AMENDMENTS

None